Jeremy Millar

Jeremy Millar

Auto-generated profile, based on publicly available information

Jeremy Millar

Bayside Health Radiation Oncology, School of Translational Medicine Monash University Melbourne Victoria Australia

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2005 in The Lancet Oncology
Verified
Journal Article
Closed access
BBBryan H Burmeister
Bryan H Burmeister
BSBernard Mark Smithers
Bernard Mark Smithers
VGVal Gebski
Val Gebski
LFLara Fitzgerald
Lara Fitzgerald
RSR John Simes
R John Simes
JDJames W Denham
James W Denham

1 June 2007 in The Lancet Oncology
Verified
Journal Article
Closed access
DDDavid P Dearnaley
David P Dearnaley
MSMatthew R Sydes
Matthew R Sydes
JGJohn D Graham
John D Graham
EAEdwin G Aird
Edwin G Aird
DBDavid Bottomley
David Bottomley
MPMahesh Kb Parmar
Mahesh Kb Parmar

15 August 2005 in The Journal of Immunology
Verified
Journal Article
Closed access
JSJayne S Sutherland
Jayne S Sutherland
GGGabrielle L Goldberg
Gabrielle L Goldberg
MHMaree V Hammett
Maree V Hammett
AUAdam P Uldrich
Adam P Uldrich
SBStuart P Berzins
Stuart P Berzins
RBRichard L Boyd
Richard L Boyd
The thymus undergoes age-related atrophy, coincident with increased circulating sex steroids from puberty. The impact of thymic atrophy is most profound in clinical conditions that cause a severe loss in peripheral T cells with the ability to regenerate adequate numbers of naive CD4+ T cells indirectly correlating with patient age. The present study demonstrates that androgen ablation results in the complete regeneration of the aged male mouse thymus, restoration of peripheral T cell phenotype and function and enhanced thymus regeneration following bone marrow transplantation. Importantly, this technique is also applicable to humans, with analysis of elderly males undergoing sex steroid ablation therapy for prostatic carcinoma, demonstrating an increase in circulating T cell numbers, particularly naive (TREC+) T cells. Collectively these studies represent a fundamentally new approach to treating immunodeficiency states in humans.

1 April 2014 in The Lancet Oncology
Verified
Journal Article
Open access
DDDavid P Dearnaley
David P Dearnaley
GJGordana Jovic
Gordana Jovic
ISIsabel Syndikus
Isabel Syndikus
VKVincent Khoo
Vincent Khoo
RCRichard A Cowan
Richard A Cowan
MSMatthew R Sydes
Matthew R Sydes
The aim of this trial was to compare dose-escalated conformal radiotherapy with control-dose conformal radiotherapy in patients with localised prostate cancer. Preliminary findings reported after 5 years of follow-up showed that escalated-dose conformal radiotherapy improved biochemical progression-free survival. Based on the sample size calculation, we planned to analyse overall survival when 190 deaths occurred; this target has now been reached, after a median 10 years of follow-up. RT01 was a phase 3, open-label, international, randomised controlled trial enrolling men with histologically confirmed T1b-T3a, N0, M0 prostate cancer with prostate specific antigen of less than 50 ng/mL. Patients were randomly assigned centrally in a 1:1 ratio, using a computer-based minimisation algorithm stratifying by risk of seminal vesicle invasion and centre to either the control group (64 Gy in 32 fractions, the standard dose at the time the trial was designed) or the escalated-dose group (74 Gy in 37 fractions). Neither patients nor investigators were masked to assignment. All patients received neoadjuvant androgen deprivation therapy for 3-6 months before the start of conformal radiotherapy, which continued until the end of conformal radiotherapy. The coprimary outcome measures were biochemical progression-free survival and overall survival. All analyses were done on an intention-to-treat basis. Treatment-related side-effects have been reported previously. This trial is registered, number ISRCTN47772397. Between Jan 7, 1998, and Dec 20, 2001, 862 men were registered and 843 subsequently randomly assigned: 422 to the escalated-dose group and 421 to the control group. As of Aug 2, 2011, 236 deaths had occurred: 118 in each group. Median follow-up was 10·0 years (IQR 9·1-10·8). Overall survival at 10 years was 71% (95% CI 66-75) in each group (hazard ratio [HR] 0·99, 95% CI 0·77-1·28; p=0·96). Biochemical progression or progressive disease occurred in 391 patients (221 [57%] in the control group and 170 [43%] in the escalated-dose group). At 10 years, biochemical progression-free survival was 43% (95% CI 38-48) in the control group and 55% (50-61) in the escalated-dose group (HR 0·69, 95% CI 0·56-0·84; p=0·0003). At a median follow-up of 10 years, escalated-dose conformal radiotherapy with neoadjuvant androgen deprivation therapy showed an advantage in biochemical progression-free survival, but this advantage did not translate into an improvement in overall survival. These efficacy data for escalated-dose treatment must be weighed against the increase in acute and late toxicities associated with the escalated dose and emphasise the importance of use of appropriate modern radiotherapy methods to reduce side-effects. UK Medical Research Council.

12 January 2012 in BJU International
Verified
Journal Article
Open access
PDF file
PGPeter Grimm
Peter Grimm
IBIgnace Billiet
Ignace Billiet
DBDavid Bostwick
David Bostwick
ADAdam Paul Dicker
Adam Paul Dicker
SFSteven Frank
Steven Frank
SLStephen Langley
Stephen Langley
What's known on the subject? and What does the study add? Very few comparative studies to date evaluate the results of treatment options for prostate cancer using the most sensitive measurement tools. PSA has been identified as the most sensitive tool for measuring treatment effectiveness. To date, comprehensive unbiased reviews of all the current literature are limited for prostate cancer. This is the first large scale comprehensive review of the literature comparing risk stratified patients by treatment option and with long‐term follow‐up. The results of the studies are weighted, respecting the impact of larger studies on overall results. The study identified a lack of uniformity in reporting results amongst institutions and centres. A large number of studies have been conducted on the primary therapy of prostate cancer but very few randomized controlled trials have been conducted. The comparison of outcomes from individual studies involving surgery (radical prostatectomy or robotic radical prostatectomy), external beam radiation (EBRT) (conformal, intensity modulated radiotherapy, protons), brachytherapy, cryotherapy or high intensity focused ultrasound remains problematic due to the non‐uniformity of reporting results and the use of varied disease outcome endpoints. Technical advances in these treatments have also made long‐term comparisons difficult. The Prostate Cancer Results Study Group was formed to evaluate the comparative effectiveness of prostate cancer treatments. This international group conducted a comprehensive literature review to identify all studies involving treatment of localized prostate cancer published during 2000–2010. Over 18 000 papers were identified and a further selection was made based on the following key criteria: minimum/median follow‐up of 5 years; stratification into low‐, intermediate‐ and high‐risk groups; clinical and pathological staging; accepted standard definitions for prostate‐specific antigen failure; minimum patient number of 100 in each risk group (50 for high‐risk group). A statistical analysis (standard deviational ellipse) of the study outcomes suggested that, in terms of biochemical‐free progression, brachytherapy provides superior outcome in patients with low‐risk disease. For intermediate‐risk disease, the combination of EBRT and brachytherapy appears equivalent to brachytherapy alone. For high‐risk patients, combination therapies involving EBRT and brachytherapy plus or minus androgen deprivation therapy appear superior to more localized treatments such as seed implant alone, surgery alone or EBRT. It is anticipated that the study will assist physicians and patients in selecting treatment for men with newly diagnosed prostate cancer.

1 June 2016 in The Lancet Oncology
Verified
Journal Article
Closed access
GDGillian M Duchesne
Gillian M Duchesne
HWHenry H Woo
Henry H Woo
JBJulie K Bassett
Julie K Bassett
SBSteven J Bowe
Steven J Bowe
CDCatherine D'ESte
Catherine D'ESte
STSandra Turner
Sandra Turner